| Co-Promotions/Collaborations
Dey, L.P.
On March 13, 2007, Critical Therapeutics and Dey, L.P. (DEY), a subsidiary of Mylan Inc., entered into a definitive co-promotion agreement that leverages the expertise of both companies in the U.S. respiratory care market.
Critical Therapeutics and DEY jointly promote ZYFLO CR™ (zileuton) extended-release tablets, the twice daily formulation of zileuton, which was launched on September 27, 2007. In addition, Critical Therapeutics co-promote DEY’s product, PerforomistTM (formoterol fumarate) Inhalation Solution. Perforomist was approved for marketing by the FDA in May 2007 and launched on October 8, 2007.
MedImmune, Inc.
In July 2003, Critical Therapeutics entered into an exclusive license and collaboration agreement with MedImmune to jointly develop products directed towards HMGB1. Under the terms of the agreement, we granted MedImmune an exclusive worldwide license, under patent rights and know-how controlled by us, to make, use and sell products, including antibodies, that bind to, inhibit or inactivate HMGB1 and are used in the treatment or prevention, but not the diagnosis, of diseases, disorders and medical conditions.
Critical Therapeutics and MedImmune determine the extent of our collaboration on research and development matters each year upon the renewal of a rolling three-year research plan. We are currently working with MedImmune to evaluate the potential of a series of monoclonal antibodies as agents for development as therapeutic antibodies to enable them to enter clinical development. Under the terms of the agreement, MedImmune has agreed to fund and expend efforts to research and develop at least one HMGB1-inhibiting product for two indications through specified clinical phases.
Beckman Coulter, Inc.
In January 2005, Critical Therapeutics and Beckman Coulter, Inc. entered into an exclusive license agreement under which Critical Therapeutics granted Beckman Coulter certain rights in its patents, patent applications and other intellectual property relating to Critical Therapeutics’ proprietary HMGB1 technology. Beckman Coulter intends to use the HMGB1 technology to develop an immunoassay for detection and management of inflammatory diseases. In February 2007, Beckman Coulter exercised its option to continue to license patent rights relating to the use HMGB1 technology and Critical Therapeutics received a product development fee. Critical Therapeutics is also entitled to receive a milestone payment upon the achievement of the first commercial sale of a licensed product and royalties on net sales of licensed products by Beckman Coulter.
|
